InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data for use in QSP modeling, analysis, or decision-making.
The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines. InSysBio team will populate its CYTOCON or fIVE databases with newly curated data, ensuring availability in the most convenient and standardized format for subsequent analysis and integration.
Key features of the deliverables (all integrated into CYTOCON DB and fIVE DB):
1. Annotated Data Tables:
2. Summary Statistics Table
3. Visualizations
Each data request follows a one-month workflow. The first week is dedicated to a feasibility assessment, during which the team evaluates the availability and volume of the requested data in scientific literature. If the data cannot be identified, clients receive detailed feedback, and the query may be refined. Depending on the scope and complexity of the request, the team can process up to 20 scientific articles per month, resulting in approximately 800 annotated concentration values for CYTOCON DB and 130 annotated parameters for fIVE DB. All annotations are performed by a dedicated team consisting of one professional annotator and one reviewer, ensuring a high standard of quality and consistency throughout the process.
For further details or to data request, please feel free to contact us: support@insysbio.com
To learn more about CYTOCON DB, please visit https://cytocon.insysbio.com/Index.aspx
To learn more about fIVE DB, please visit https://5db.insysbio.com/Index.aspx
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | March 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
1.
19 Mar 2025 15:40
The project aims at mechanistic modeling of antibodies to predict pharmacokinetics and target occupancy in cerebrospinal fluid
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease
|
20
|
21
|
22
|
23
|
|
24
|
25
|
26
1.
26 Mar 2025 00:12
InSysBio to participate in AACR 2025
InSysBio announces its participation in AACR Annual Meeting 2025 which is to be held from April 25-30, 2025, at McCormick Place Convention Center, Chicago, Illinois, USA. InSysBio team is going to present their QSP modeling services and software to optimize drug development at Booth #4845 and 3 posters in frames of the Meeting
|
27
|
28
|
29
|
30
|
|
31
1.
31 Mar 2025 15:17
Now the Immunological Synapse submodels are meaningfully improved
InSysBio launches Immune Response Template (IRT) version 3.7.0. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system. IRT v.3.7.0 gets a range of new features.
| ||||||